Form 8.3 -Xeris Pharmaceuticals Inc 27 May 2021 - GlobeNewswire

thekflow.blogspot.com

                FORM 8.3

 

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1. KEY INFORMATION

 

Name of person dealing (Note 1)	State Street Global Advisors & Affiliates
Company dealt in	Xeris Pharmaceuticals Inc
Class of relevant security to which the dealings being disclosed relate (Note 2)	$0.001 common stock
Date of dealing	26th May 2021

 

 

2. INTERESTS AND SHORT POSITIONS

 

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	1,001,326	1.50866%
(2) Derivatives (other than options)	N/A
(3) Options and agreements to purchase/sell	N/A
Total	1,001,326	1.50866%

 

 

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

 

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	N/A
(2) Derivatives (other than options)	N/A
(3) Options and agreements to purchase/sell	N/A
Total	N/A

 

 

3. DEALINGS (Note 4)

 

(a) Purchases and sales

 

Purchase/sale	Number of relevant securities	Price per unit (Note 5)
Sale	220	3.33

(b) Derivatives transactions (other than options transactions)

 

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)
N/A

 

 

(c) Options transactions in respect of existing relevant securities

 

(i) Writing, selling, purchasing or varying

 

Product name, e.g. call option	Writing, selling, purchasing varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)
N/A

 

 

(ii) Exercising

 

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)
N/A

 

 

(d) Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)
N/A

 

 

4. OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

N/A

 

 

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached? (Note 9)	NO
Date of disclosure	27th May 2021
Contact name	Colin Fernandes
Telephone number	020 33956221
If a connected EFM, name of offeree/offeror with which connected	N/A
If a connected EFM, state nature of connection (Note 10)	N/A

 

Adblock test (Why?)

"may" - Google News
May 27, 2021 at 09:11PM
https://ift.tt/2Sz7EXf

Form 8.3 -Xeris Pharmaceuticals Inc 27 May 2021 - GlobeNewswire
"may" - Google News
https://ift.tt/3foH8qu
https://ift.tt/2zNW3tO

Bagikan Berita Ini